Literature DB >> 29916122

Outer nuclear layer thickness at the central fovea relation with symptom duration in central serous chorioretinopathy.

Ibrahim Ozdemir1, Ayla Eren2, Giray Ersöz3.   

Abstract

PURPOSE: To evaluate a relation between the outer nuclear layer (ONL) thickness and symptom duration in patients with central serous chorioretinopathy (CSC) using spectraldomain optical coherence tomography (SDOCT) and to compare with healthy subjects.
METHODS: This retrospective study included 67 CSC patients and 20 healthy subjects. The ONL thickness was measured between internal limiting membrane and external limiting membrane at central fovea using SD-OCT (Topcon 3D OCT-2000, Japan). The patients were divided into six groups based on symptom duration: group (1) contained 14 patients (symptom duration between 1 and 30 days) , group (2) contained 11 patients (symptom duration between 31 and 60 days), group (3) contained 12 patients (symptom duration between 61 and 90 days) , group (4) contained 11 (symptom duration between 91 and 120 days), group (5) contained 7 patients (symptom duration between 121 and 150 days) and group (6) contained 12 (symptom duration between 151 days and more).
RESULTS: The average ONL thickness was 76.1 ± 16.8 μm in CSC in all patients and 122.4 ± 2.8 μm in healthy subjects. The major differences were between group (3) and (4) (p < 0.001). The ONL thickness was negatively correlated with symptom duration (rs = - 0.918; p< 0.001). In addition, the ONL thickness was positively correlated with BCVA (rs = 0.619; p< 0.001).
CONCLUSION: Photoreceptor loss could begin within the first 3 months in CSC.

Entities:  

Keywords:  Central serous chorioretinopathy; Eplerenone; Outer nuclear layer; Symptom duration

Mesh:

Year:  2018        PMID: 29916122     DOI: 10.1007/s10792-018-0950-y

Source DB:  PubMed          Journal:  Int Ophthalmol        ISSN: 0165-5701            Impact factor:   2.031


  7 in total

1.  Optical coherence tomography parameters as predictors of treatment response to a 577-nm subthreshold micropulse laser in chronic central serous chorioretinopathy.

Authors:  Meltem Guzin Altınel; Banu Acikalin; Hasan Gunes; Gokhan Demir
Journal:  Lasers Med Sci       Date:  2021-01-07       Impact factor: 3.161

2.  Dynamic changes and correlation analysis of outer retinal microstructure in macular area of central serous chorioretinopathy patients during restoration period.

Authors:  Chuangxin Huang; Lijun Zhou; Zhen Tian; Kunbei Lai; Xiaojing Zhong; Fabao Xu; Yajun Gong; Longhui Li; Chenjin Jin
Journal:  Int Ophthalmol       Date:  2021-01-08       Impact factor: 2.031

3.  Outer Nuclear Layer as the Main Predictor to Anatomic Response to Half Dose Photodynamic Therapy in Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Ana Rita Viana; Joana Pires; Carla Ferreira; Lara Queirós; Manuel Falcão
Journal:  J Ophthalmol       Date:  2019-10-13       Impact factor: 1.909

4.  Changes in the Foveal Outer Nuclear Layer of Central Serous Chorioretinopathy Patients Over the Disease Course and Their Response to Photodynamic Therapy.

Authors:  Kaixin Deng; Yufei Gui; Yi Cai; Zhiqiao Liang; Xuan Shi; Yaoyao Sun; Mingwei Zhao
Journal:  Front Med (Lausanne)       Date:  2022-01-14

5.  532-nm Subthreshold Micropulse Laser for the Treatment of Chronic Central Serous Retinopathy.

Authors:  Keissy Sousa; Gil Calvão-Santos; Marina João; Nuno Gomes; Manuel Falcão
Journal:  Clin Ophthalmol       Date:  2020-02-25

6.  Predictive factors of metamorphopsia after reduced-fluence photodynamic therapy in patients with central serous chorioretinopathy with good baseline visual acuity.

Authors:  Mayuka Hayashida; Akiko Miki; Shunichiro Nakai; Wataru Matsumiya; Hisanori Imai; Sentaro Kusuhara; Makoto Nakamura
Journal:  PLoS One       Date:  2020-10-12       Impact factor: 3.240

7.  Clinical Factors Associated with Low-Contrast Visual Acuity after Reduced-Fluence Photodynamic Therapy in Patients with Resolved Central Serous Chorioretinopathy and Good Baseline Visual Acuity.

Authors:  Aya Chubachi; Akiko Miki; Mayuka Hayashida; Mari Sakamoto; Hisanori Imai; Sentaro Kusuhara; Makoto Nakamura
Journal:  Pharmaceuticals (Basel)       Date:  2021-03-28
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.